<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND STUDY AIMS: <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is a <z:e sem="disease" ids="C0032927" disease_type="Neoplastic Process" abbrv="">premalignant condition</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The risk of developing high grade intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (HGIN) or <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is currently a matter of debate </plain></SENT>
<SENT sid="2" pm="."><plain>Due to several shortcomings, previous studies have probably overestimated the risk </plain></SENT>
<SENT sid="3" pm="."><plain>The main aim of our study was to investigate the incidence of HGD and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in a cohort of patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>PATIENTS AND METHODS: In a prospective, cohort study, <z:hpo ids='HP_0000001'>all</z:hpo> patients had <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> and macroscopic evidence of short- or long-segment (&lt; 3 cm or &gt; or = 3 cm) <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent a standard protocol including regular endoscopies with biopsies and were treated with a <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> or antireflux surgery </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: A total of 135 patients underwent 623 endoscopies during 700 patient-years (mean follow-up 5.2 +/- 2.3 years) </plain></SENT>
<SENT sid="7" pm="."><plain>Simultaneous HGIN and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> were detected in two patients with long-segment <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (1.5%; 2 and 6 years after the index endoscopy) </plain></SENT>
<SENT sid="8" pm="."><plain>Low grade intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (LGIN) was detected in 25 patients (18.5%); in 11 of these patients (44%), LGIN was not confirmed in later biopsies </plain></SENT>
<SENT sid="9" pm="."><plain>Our study shows an incidence of HGIN/<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of 1/350 patient-years </plain></SENT>
<SENT sid="10" pm="."><plain>Endoscopic regression of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> was seen in 20.7% of patients </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: The incidence of HGIN/<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is low in patients with adequately treated <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>The annual risk of developing HGIN/<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is 0.21% (1.6% in long-segment <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>) </plain></SENT>
</text></document>